Focused On-demand Library for Probable ATP-dependent RNA helicase DDX6

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P26196

UPID:

DDX6_HUMAN

Alternative names:

ATP-dependent RNA helicase p54; DEAD box protein 6; Oncogene RCK

Alternative UPACC:

P26196; Q5D048

Background:

Probable ATP-dependent RNA helicase DDX6, also known as ATP-dependent RNA helicase p54, DEAD box protein 6, and Oncogene RCK, plays a pivotal role in RNA metabolism. It is essential for the formation of P-bodies, cytoplasmic structures involved in the storage and regulation of mRNAs. DDX6 coordinates the storage of translationally inactive mRNAs, preventing their degradation and plays a role in mRNA decapping. Additionally, it blocks autophagy in nutrient-rich conditions by repressing the expression of ATG-related genes.

Therapeutic significance:

DDX6 is implicated in Intellectual developmental disorder with impaired language and dysmorphic facies, a condition characterized by intellectual disability, developmental delay, and dysmorphic features. Understanding the role of DDX6 could open doors to potential therapeutic strategies for this disorder.